1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Introduction
2.2. Define: Research Objective
2.3. Determine: Research Design
2.4. Prepare: Research Instrument
2.5. Collect: Data Source
2.6. Analyze: Data Interpretation
2.7. Formulate: Data Verification
2.8. Publish: Research Report
2.9. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising geriatric population and increasing incidence of the syndrome
5.1.1.2. Improvements in healthcare services and advancements in stem cell transplantation and radiation therapy
5.1.1.3. Easy of availability and access to novel treatments
5.1.2. Restraints
5.1.2.1. High cost of novel therapeutics
5.1.3. Opportunities
5.1.3.1. Development of strong drug pipeline
5.1.3.2. Supportive government initiatives such as reimbursement policies
5.1.4. Challenges
5.1.4.1. Complexity and heterogeneity of novel treatment
5.2. Cumulative Impact of COVID-19

6. Myelodysplastic Syndrome Market, by Route of Administration
6.1. Introduction
6.2. Oral
6.3. Parenteral

7. Myelodysplastic Syndrome Market, by Drug Class
7.1. Introduction
7.2. Alkylating Agents
7.3. Cytotoxic Antibiotics
7.4. Topoisomerase Inhibitors

8. Americas Myelodysplastic Syndrome Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Myelodysplastic Syndrome Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand

10. Europe, Middle East & Africa Myelodysplastic Syndrome Market
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom

11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion

12. Company Usability Profiles
12.1. Acceleron Pharma
12.2. Amgen
12.3. Bellicum Pharmaceuticals
12.4. BioLineRx
12.5. Celator Pharmaceuticals
12.6. Celgene
12.7. Cornerstone Pharmaceuticals
12.8. Eli-Lilly
12.9. GlaxoSmithKline
12.10. Novartis

13. Appendix
13.1. Discussion Guide
13.2. License & Pricing

List of Figures

FIGURE 1. GLOBAL MYELODYSPLASTIC SYNDROME MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL MYELODYSPLASTIC SYNDROME MARKET: MARKET DYNAMICS
FIGURE 3. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2020 VS 2027 (%)
FIGURE 4. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2020 VS 2027 (USD MILLION)
FIGURE 5. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2027
FIGURE 6. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ORAL, 2018-2027 (USD MILLION)
FIGURE 7. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ORAL, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 8. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PARENTERAL, 2018-2027 (USD MILLION)
FIGURE 9. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PARENTERAL, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 10. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2020 VS 2027 (%)
FIGURE 11. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2020 VS 2027 (USD MILLION)
FIGURE 12. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2027
FIGURE 13. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ALKYLATING AGENTS, 2018-2027 (USD MILLION)
FIGURE 14. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 15. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CYTOTOXIC ANTIBIOTICS, 2018-2027 (USD MILLION)
FIGURE 16. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CYTOTOXIC ANTIBIOTICS, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 17. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2027 (USD MILLION)
FIGURE 18. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 19. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 20. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 21. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 22. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 23. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 24. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 25. ASIA-PACIFIC MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 26. AUSTRALIA MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 27. CHINA MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 28. INDIA MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 29. INDONESIA MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 30. JAPAN MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 31. MALAYSIA MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 32. PHILIPPINES MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 33. SINGAPORE MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 34. SOUTH KOREA MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 35. TAIWAN MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 36. THAILAND MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 37. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 38. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 39. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 40. ITALY MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 41. NETHERLANDS MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 42. QATAR MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 43. RUSSIA MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 44. SAUDI ARABIA MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 45. SOUTH AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 46. SPAIN MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 47. UNITED ARAB EMIRATES MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 48. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 49. GLOBAL MYELODYSPLASTIC SYNDROME MARKET: FPNV POSITIONING MATRIX
FIGURE 50. GLOBAL MYELODYSPLASTIC SYNDROME MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 51. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL MYELODYSPLASTIC SYNDROME MARKET, BY TYPE

List of Tables

TABLE 1. GLOBAL MYELODYSPLASTIC SYNDROME MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
TABLE 3. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 4. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ORAL, BY REGION, 2018-2027 (USD MILLION)
TABLE 5. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2027 (USD MILLION)
TABLE 6. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 7. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2027 (USD MILLION)
TABLE 8. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CYTOTOXIC ANTIBIOTICS, BY REGION, 2018-2027 (USD MILLION)
TABLE 9. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY REGION, 2018-2027 (USD MILLION)
TABLE 10. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 11. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 12. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 13. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 14. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 15. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 16. ASIA-PACIFIC MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 17. AUSTRALIA MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 18. CHINA MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 19. INDIA MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 20. INDONESIA MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 21. JAPAN MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 22. MALAYSIA MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 23. PHILIPPINES MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 24. SINGAPORE MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 25. SOUTH KOREA MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 26. TAIWAN MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 27. THAILAND MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 28. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 29. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 30. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 31. ITALY MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 32. NETHERLANDS MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 33. QATAR MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 34. RUSSIA MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 35. SAUDI ARABIA MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 36. SOUTH AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 37. SPAIN MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 38. UNITED ARAB EMIRATES MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 39. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 40. GLOBAL MYELODYSPLASTIC SYNDROME MARKET: SCORES
TABLE 41. GLOBAL MYELODYSPLASTIC SYNDROME MARKET: BUSINESS STRATEGY
TABLE 42. GLOBAL MYELODYSPLASTIC SYNDROME MARKET: PRODUCT SATISFACTION
TABLE 43. GLOBAL MYELODYSPLASTIC SYNDROME MARKET: RANKING
TABLE 44. GLOBAL MYELODYSPLASTIC SYNDROME MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 45. GLOBAL MYELODYSPLASTIC SYNDROME MARKET: MERGER & ACQUISITION
TABLE 46. GLOBAL MYELODYSPLASTIC SYNDROME MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 47. GLOBAL MYELODYSPLASTIC SYNDROME MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 48. GLOBAL MYELODYSPLASTIC SYNDROME MARKET: INVESTMENT & FUNDING
TABLE 49. GLOBAL MYELODYSPLASTIC SYNDROME MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 50. GLOBAL MYELODYSPLASTIC SYNDROME MARKET: LICENSE & PRICING

Companies Mentioned

Acceleron Pharma
Amgen
Bellicum Pharmaceuticals
BioLineRx
Celator Pharmaceuticals
Celgene
Cornerstone Pharmaceuticals
Eli-Lilly
GlaxoSmithKline
Novartis